Tag Archives: Pharmacovigilance

Bisphosphonates and other Osteoporosis news

:Original raster version: :Image:Food and Drug...

Image via Wikipedia

Latest news

 


In the States, the FDA (Food and Drug advisory committee) wants the agency to limit the duration of bisphosphonate therapy for treatment of osteoporosis.

But the committee could not agree on what that time limit should be.  However, their findings are below.

While in Britain, there are very, very small signs that the ‘new’ NHS                                                                                                                  might be looking for ways  to increase revenue from hospitals, and osteoporosis patients could benefit.

Exercise for Osteoporosis

With the NHS desperately looking for ideas to increase funding, now is the time to hit hospitals with ideas to provide exercise classes for those with osteopororis.  Even – what a revolutionary idea! – help prevent patients getting the disease.

Called to a discussion with a Foundation Hospital, it was evident that they were finally receptive to ideas to increase revenue.  Talking over requirements for exercise classes, their eyes lit up when I cited another hospital where patients were willing to pay £7 or £8 for other classes, provided they could come in every week.  There had been talk about this being a ‘club’ whose members only met to gossip – but when it was pointed out that this ‘club’ were happy to pay the fees ad infinitum as long as they could feel they were getting exercise, ideas changed.

This also meant that once patients had received a referral letter, they then went on to pay for classes so there would be no need to stop after six weeks for usual referrals.  Once set up, the classes could continue without much administration.

What is needed

Hospital gym with suitable exercise equipment :  with

  • treadmill
  • wobble boards
  • bouncer
  • anything encouraging weight-bearing exercises

A physio to supervice, set the class in motion, give out exercises that progress from 5 – 10 different stations, then give call when it is time to move to next station.  Once first induction class was over, generally patients followed a pattern themselves, and only needed ‘keeping an eye on’.

Once set up, regular patients knew exactly what they need to do, and were content to move around the room when given ‘time up’ signal.

How to find members

Initial administration costs would come with finding patients willing to take classes.  In this area these came via LINk, OAPs clubs, GP referral, Cancer support centres, word of mouth, etc.  Signs are that more classes are going to have to be organised.

Times

If the gym is fully utilised, these classes can easily take place after normal closing time – say 4 pm to 8 pm.

There were plenty of Physios happy to supervise if they received overtime payment.

What Patients can do

Set up a discussion with the hospital Chief Executive;  and/or PALS.  Get Governors involved, or if there is one – the hospital Patients’ Association.  Ask your GP to lobby.

Find out from Physios if they would be prepared to supervise classes – and possibly work overtime in the evening.

Get a list of possible class members.

Then present this to the hospital – and Good Luck!

BISPHOSPHONATES

Earlier this year, the FDA in America required that all bisphosphonates used to prevent or treat osteoporosis warn on their labels that optimal duration of use hasn’t been determined, and that all patients on bisphosphonate therapy should have their need for continued therapy re-evaluated periodically.

This issue has become a hot potato for the FDA, as reports have emerged linking long-time bisphosphonate therapy with increased risk of atypical fractures.

The Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee has discussed whether emerging reports of adverse events should spur the FDA to change the label to indicate that the drug should not be used long term.

Committee members voted 17-6 to endorse a label change — but then backed away from setting a hard deadline, citing a lack of data to pinpoint an ideal therapeutic time limit.

Placebo-controlled trials typically provide data for only five years of therapy, but there is no strong clinical evidence that bisphosphonates work better after they’re used for a long period of time, nor is there firm evidence that long-term use causes harm, the panel said.

Bisphosphonates are prescribed to some five million patients annually to stave off or treat osteoporosis and are highly effective at reducing the risk of osteoporotic fractures. In the States, brand-names Actonel, Atelvia, Boniva, and Reclast, have been shown to reduce the risk of breaking a hip by 40% to 50% and fracturing a vertebra by between 40% and 70% by inhibiting bone resorption to prevent loss of bone mass.

Latest information

In 2010, the FDA required makers of bisphosphonate drugs to add a warning to their labels about a small increased risk of atypical femur fractures after an American Society for Bone and Mineral Research task force concluded that the risk, although it is small, is real.

The panel heard from women who were taking bisphosphonates to prevent osteoporosis when suddenly and painfully, they broke their femurs. One woman was on a subway train that screeched to a halt, and as her weight was thrust onto one leg, her femur snapped and she collapsed. Other women had similar stories — a teacher reaching something in front of her students, a grandmother taking a large step to walk toward her grandchild, a woman walking down a front stoop to pick up the morning newspaper — and in each case the women collapsed to the ground as their femurs snapped.

The panel was also concerned with the drug’s link to deterioration of the jawbone. In 2005, the FDA added a warning on bisphosphonates about osteonecrosis of the jaw, a rare disease in which the bone in the jaw dies. In data presented Friday, an FDA reviewer said the risk for osteonecrosis of the jaw appears more prevalent after four years or more of use.

There are also some data suggesting a link to long-term use of bisphosphonates and esophageal cancer, although solid evidence is lacking, the panel said. In 2009, a study in the New England Journal of Medicine used data from FDA’s Adverse Event Reporting System to identify and describe 23 patients taking alendronate who were diagnosed with esophageal cancer.

Findings

Taken together, there’s no clear answer on the long-term safety of bisphosphonate therapy for the prevention and treatment of osteoporosis, the panel said and called for more studies to hone in on the long-term risks and benefits of the drug.

“There’s no doubt that these are very efficacious drugs that reduce fractures and mortality, and there are many women who should be on these drugs that aren’t on them,” said Sonia Hernandez Diaz, MD, associate professor of epidemiology at Harvard School of Public Health. “But what we’re talking about today is using these drugs for more than three years, and I’m not convinced at all that there are any good data that, even for subgroups of patients, they should be continued [past three years].”

The panel was also asked to discuss the idea of a “drug holiday” or taking a break for bisphosphonate treatment in order to minimize risks, but agreed there wasn’t enough evidence to warrant recommending a drug holiday as a treatment plan.

More information:  http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203891.htm

Enhanced by Zemanta